成纤维细胞激活蛋白抑制剂(FAPI)放射性药物与[18F]FDG在妇科恶性肿瘤中的头对头比较:系统文献综述与荟萃分析
该系统综述与荟萃分析检索截至2024年10月25日的文献,比较FAPI放射性药物与[18F]FDG PET在妇科癌症中的诊断性能,共纳入10项研究进行定性评估、5项卵巢癌研究进入荟萃分析。卵巢癌原发肿瘤中68Ga-FAPI与[18F]FDG的合并灵敏度为95%对92%、合并特异度均为81%;腹膜转移的合并灵敏度为97%对70%、合并特异度为93%对88%。作者认为FAPI放射性药物是[18F]FDG的有前景的替代选择,但需更大规模前瞻性研究证实。
要点
- 卵巢癌原发肿瘤:68Ga-FAPI与[18F]FDG合并灵敏度95%对92%,合并特异度均为81%。
- 卵巢癌腹膜转移:68Ga-FAPI与[18F]FDG合并灵敏度97%对70%,合并特异度93%对88%。
- 宫颈癌淋巴结转移检测中68Ga-FAPI高于[18F]FDG,腹膜癌指数视觉评估中68Ga-FAPI显示更大肿瘤负荷。
核心结论
- 尽管文献数据有限,基于FAPI的放射性药物是[18F]FDG用于妇科癌症成像的有前景的替代选择,尤其在宫颈癌和卵巢癌淋巴结转移检测及卵巢癌腹膜转移检测方面。
- 需要更大规模的前瞻性研究来证实这些结果并促进FAPI放射性药物纳入临床实践。
研究设计与样本
- 系统文献综述与荟萃分析,检索PubMed/MEDLINE和EMBASE并更新至2024年10月25日,纳入评估FAPI与[18F]FDG PET/CT或PET/MR在妇科癌症患者中应用的临床研究。
- 共纳入10项研究进行定性评估,其中5项聚焦卵巢癌的研究纳入荟萃分析。
- 使用QUADAS-2工具(诊断准确性研究质量评估)评估质量,计算病灶层面的合并灵敏度、特异度、阳性预测值和阴性预测值及95%置信区间。
主要发现
- 原发宫颈癌的检出率在两种放射性药物中均为96%至100%。
- 卵巢癌原发肿瘤:68Ga-FAPI与[18F]FDG的合并灵敏度分别为95%和92%,合并特异度均为81%。
- 宫颈癌淋巴结转移检测中68Ga-FAPI高于[18F]FDG。
- 卵巢癌淋巴结转移:68Ga-FAPI与[18F]FDG的合并灵敏度分别为97%和88%,合并特异度分别为83%和41%。
- 卵巢癌腹膜转移:68Ga-FAPI与[18F]FDG的合并灵敏度分别为97%和70%,合并特异度分别为93%和88%;腹膜癌指数等视觉评估中68Ga-FAPI显示更大肿瘤负荷。
关键数值与推荐
- 卵巢癌原发肿瘤合并灵敏度:68Ga-FAPI 95%,[18F]FDG 92%;合并特异度均为81%。
- 卵巢癌淋巴结转移合并灵敏度:68Ga-FAPI 97%,[18F]FDG 88%;合并特异度:68Ga-FAPI 83%,[18F]FDG 41%。
- 卵巢癌腹膜转移合并灵敏度:68Ga-FAPI 97%,[18F]FDG 70%;合并特异度:68Ga-FAPI 93%,[18F]FDG 88%。
- 原发宫颈癌检出率:两种放射性药物均为96%至100%。
临床怎么用
- 作者认为FAPI放射性药物是[18F]FDG用于妇科癌症成像的有前景的替代选择,尤其在宫颈癌和卵巢癌淋巴结转移检测及卵巢癌腹膜转移检测方面。
- 作者指出需要更大规模的前瞻性研究来证实这些结果并促进FAPI放射性药物纳入临床实践。
局限性
- 原文指出文献数据有限。
- 原文结论指出需要更大规模的前瞻性研究来证实这些结果并促进FAPI放射性药物纳入临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to systematically review and perform a meta-analysis to compare the diagnostic performance of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) in gynaecological cancers. METHODS: A comprehensive search of PubMed/MEDLINE and EMBASE was conducted and updated to October 25, 2024, to identify clinical studies evaluating FAPI and [18F]FDG PET/CT or PET/MR in patients with gynaecological cancer. Quality was assessed using the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies). Per-lesion pooled estimates of sensitivity, specificity, positive predictive value, and negative predictive value were calculated with 95% confidence intervals. RESULTS: Ten studies were included for qualitative assessment and five studies focusing on ovarian cancer were included in the meta-analysis. The detection rates of primary cervical cancer ranged from 96 to 100% for both radiopharmaceuticals. For the primary tumour in ovarian cancer, the pooled sensitivities of 68Ga-FAPI and [18F]FDG were 95% and 92%, and the pooled specificities were 81% for both radiopharmaceuticals. Nodal metastases detection was higher with 68Ga-FAPI compared with [18F]FDG in cervical cancer. Similarly, in ovarian cancer the estimated pooled sensitivities of 68Ga-FAPI and [18F]FDG were 97% and 88%, and the pooled specificities were 83% and 41%, respectively. At peritoneal metastases analysis in ovarian cancer, the pooled sensitivities of 68Ga-FAPI and [18F]FDG were 97% and 70%, and the pooled specificities were 93% and 88%, respectively. At the visual assessment of peritoneal cancer scores, such as peritoneal cancer index, 68Ga-FAPI detected a greater tumour burden compared with [18F]FDG. A comparative analysis of the PET semiquantitative parameters was also performed. CONCLUSION: Despite limited literature data, radiopharmaceuticals based on FAPIs are a promising alternative to [18F]FDG for imaging gynaecological cancers, in particular for the detection of nodal metastases in cervical and ovarian cancers, as well as for detecting peritoneal metastases in ovarian cancers. Larger prospective studies are needed to confirm these results and promote the inclusion of FAPI radiopharmaceuticals in clinical practice. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Florit A, de Koster EJ, Sassano S, et al. Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [18F]FDG in gynaecological malignancies: systematic literature review and meta-analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40278857. doi:10.1007/s00259-025-07277-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。